Therefore, our results showed that silencing of MZT2B results in decreased cell viability, impaired proliferative capacity, cell cycle arrest, and reduced migratory potential in both primary and immortalized NSCLC cells. Here, MZT2B is linked to non-small cell lung carcinoma.